Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Pharmaceutical industry news

Show

From To
GSK flags up pipeline as HIV drugs help it beat profit forecasts

GlaxoSmithKline moved to reclaim its prowess as a research powerhouse on Wednesday by flagging up dozens of new drugs and vaccines in development, as demand for new HIV medicines helped it beat quarterly profit forecasts.

Published
5 hours ago
From
Reuters
Gilead Profit Tops Estimates as Hepatitis C Drug Sales Surge

Gilead Sciences Inc., maker of the hepatitis C drugs Sovaldi and Harvoni, posted second-quarter profit that topped analysts’ estimates as revenue surged. Gilead raised its sales forecast for the year.

Published
6 hours ago
From
Bloomberg
Gilead Limits Enrollment in its Hep C Patient Program to Pressure Insurers

In a bid to push back against payers, Gilead Sciences is limiting enrollment to its patient assistance program for hepatitis C drugs, which helps people obtain the Sovaldi and Harvoni treatments when they lack sufficient insurance coverage or the financial wherewithal to get the medicines otherwise.

Published
20 July 2015
From
Wall Street Journal Pharmalot blog
TAG Pipeline Report

2015 report on the pipeline for new HIV, HCV and TB drugs.

Published
17 July 2015
From
TAG
One step further towards an HIV vaccine: and this one performed as expected

A recent experimental HIV vaccine protected 50% of a group of twelve rhesus monkeys from infection by Simian Immunodeficiency Virus (SIV). Furthermore, it did so by providing

Published
14 July 2015
By
Gus Cairns
Bold goal of stopping HIV is motivating great science

The massive challenge of finding an HIV vaccine has unleashed stunning creativity in laboratories all over the world. While we work toward the long-term goal of a vaccine, we are also pulling in partners from many sectors to improve prevention, treatment, and access to options in the short term.

Published
13 July 2015
From
Devex
Success at Glaxo's HIV Unit May Mean Having to Call It Quits

HIV drugs are proving to be so effective in containing the virus that GlaxoSmithKline Plc foresees a time, a decade away, when its most profitable business unit may no longer have a purpose.

Published
10 July 2015
From
Bloomberg
Bristol-Myers to stop new antiviral drug research

Bristol-Myers Squibb said on Thursday that it would stop efforts to find new antiviral drugs and cut 100 related jobs. The company said it will also discontinue its Hepatitis B and HIV early programs.

Published
26 June 2015
From
Reuters
China rejects Gilead hepatitis C drug patent: advocacy group

China has rejected a Gilead Sciences Inc patent application related to its costly hepatitis C drug, a U.S. advocacy group said, adding the move may lead to other countries to consider rejecting patents for the controversial treatment.

Published
19 June 2015
From
Reuters
Don’t Weaken the F.D.A.’s Drug Approval Process

The 21st Century Cures Act could substantially lower the standards for approval of many medical products, potentially placing patients at unnecessary risk of injury or death. While the legislation does not mandate this approach, it opens the door to it.

Published
12 June 2015
From
New York Times
← First12345...78Next →

Filter by country